PHILADELPHIA / LONDON (IT BOLTWISE) – A new study from the University of Pennsylvania shows that tirzepatide, a drug used to treat type 2 diabetes, temporarily suppresses neuronal activity in the brain’s reward system. This discovery could open up new avenues for treating eating disorders, although the effect is not permanent.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
In a rare study that examined brain activity in a patient with treatment-resistant obesity and loss of eating control, tirzepatide, a GLP-1 and GIP receptor agonist, was found to temporarily suppress activity in the brain’s reward system. These findings come from the University of Pennsylvania, where researchers implanted electrodes in a patient’s brain to observe the drug’s effects in real time.
The drug, originally developed to treat type 2 diabetes, showed a striking but short-lived effect on neuronal signals in the nucleus accumbens, a central area of the reward system. After five months, both the eating sounds and the corresponding neural patterns returned, suggesting that the drug’s effects are not permanent.
These results shed new light on the way GLP-1 and GIP inhibitors affect the human brain and underscore the need to develop more durable treatments for impulsivity in eating disorders. Despite the promising evidence for potential treatment of impulse disorders, these medications are currently not optimal for the long-term control of eating-related impulses.
The study provides valuable insight into how these drugs work in the brain and will guide future research in this area. However, until we better understand how these drugs work in the brain, it is too early to consider them as miracle cures for conditions other than type 2 diabetes and obesity.
Order an Amazon credit card without an annual fee with a credit limit of 2,000 euros!
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “Tirzepatide: Temporary suppression of food cravings in the brain”.